In this guide
The market is real, the margins are not what the slides say#
KFF tracking polls put GLP-1 awareness above 80% of US adults and current use at roughly 6%, with another 5–8% having tried and discontinued. 1 For an independent clinic with even mild brand presence, demand is not the bottleneck — operational economics are.
Vendor and franchise pro-formas typically quote $400+ per patient per month in net margin. Real clinic data we see in audits is $180–$320 after honest accounting for: supply cost (when sourced legally), 10–15 minutes of RN/NP time monthly, clinical labor for lab review, EHR/payment platform fees, and the no-show rate on monthly check-ins. 2
The four things that separate profitable programs from churn-heavy ones#
1. Lab cadence built into the price. Baseline + 90-day labs are non-negotiable clinically and operationally — bundled pricing protects margin and adherence both. 2. Monthly visit attached to the refill, not optional. Programs that let patients skip the check-in see discontinuation jump 15–25 points by month 6. 3 3. Supply continuity. Programs built on compounded semaglutide or tirzepatide during the FDA shortage are now structurally exposed — shortages ended in late 2024–2025, and 503A compounding for these molecules is largely no longer permissible. Source from the manufacturer's direct-pay programs (Eli Lilly LillyDirect, Novo Nordisk patient assistance) or a licensed specialty pharmacy. 45 4. A defined off-ramp protocol. The clinical and commercial case for indefinite use is weak for most patients. A documented dose-taper plus maintenance-coaching plan keeps patients in the practice after they stop the drug and converts them into a higher-margin maintenance line.
What the unit economics actually look like#
Reference month for a steady-state cash-pay program at 200 active patients: • Patient pays $399/month bundled (visit + labs amortized + medication). • Medication cost (LillyDirect direct-pay tirzepatide at the time of writing, varies by dose and program): $349–$549. • Net before labor on direct-pay supply: typically negative at the manufacturer-cash price. 5 • The viable cash-pay model is therefore visit-only ($199–$299/month) plus patient self-procures medication via direct-pay or specialty pharmacy. Net per active patient: $140–$250/month after RN time, lab, and platform.
On a 200-patient panel that is $28K–$50K/month — meaningful, durable, but materially lower than the franchise pitch. Insurance-pay programs (with prior auth and PBM step therapy) produce higher per-patient revenue but 3–6x the operational burden; most independents net less from insurance-pay than from a clean cash-pay model.
The legal and supply landscape — read this before launch#
FDA officially declared the semaglutide shortage resolved in February 2025 and tirzepatide shortage resolved in October 2024 (status reviewed and reaffirmed). Section 503A and 503B compounding of these molecules under the shortage exemption is no longer broadly permitted. Programs sourcing from compounders after the resolution date face FDA, state board, and tort exposure. 4
Manufacturer direct-pay programs (Eli Lilly's LillyDirect for Zepbound vials, Novo Nordisk's NovoCare for Wegovy) are now the safest cash-pay sourcing path for most patients. 56
Decision framework#
Run the New service feasibility report against your panel before signing any program contract. A program that pencils at $400/patient/month on a vendor slide and at $180 in your actual model is a different decision.
Run this for your clinic
Reading is free. The dollar figure for your practice requires a qualified diagnostic report.
Qualified full audits start at $1,500 per location. Refunded if quantified opportunity is under five times the fee; opportunities.
Written by
Jack Gierlich· Founder, Clear Median
Founder of Clear Median. Has built and reviewed diagnostic reports for independent primary care, specialty, and aesthetic clinics across the US. Background in operations and revenue analytics for ambulatory practices.
Reviewed by
Clear Median Analyst Team
Multi-specialty analyst team that builds the underlying benchmarks and stress-tests every recommendation against MGMA, CMS, and internal peer data before delivery.
How we write these →Frequently asked
- Can we still use a compounding pharmacy?
- For tirzepatide and semaglutide specifically, the FDA shortage that authorized 503A compounding has ended. State boards and FDA enforcement are actively reviewing this category. Other GLP-1 molecules and individualized prescriptions for documented allergies to inactive ingredients remain a narrow exception. Verify with your state board and counsel. 4
- What share of patients actually stay on a year later?
- Pharmacy-claims-based studies show 35–50% adherence at 12 months across commercial populations; structured clinic programs with mandatory monthly visits run 60–70%. 3
- Is a separately branded weight-management sub-brand worth it?
- For traditional primary care: usually yes. The brand drift of bolting cash-pay weight management onto a Medicare-heavy primary care identity costs more in front-desk friction and Google profile dilution than a $99 separate domain.
Sources & references
6 sources
- 1KFF Health Tracking Poll — GLP-1 Drugs· Kaiser Family Foundation
- 2Real-world economics of obesity pharmacotherapy programs· JAMA Health Forum
- 3Adherence and persistence with GLP-1 RAs in commercial claims· Blue Health Intelligence / Prime Therapeutics
- 4FDA Drug Shortage status — semaglutide and tirzepatide· U.S. FDA
- 5LillyDirect Self-Pay Pharmacy — Zepbound single-dose vials· Eli Lilly
- 6NovoCare Pharmacy — Wegovy self-pay· Novo Nordisk
Reimbursement figures cite CMS-published rates at the time of writing and are not locality-adjusted. Clear Median guides are educational and not legal, billing, or medical advice. Confirm any code or rate against your contracts and current CMS fee schedules before acting.